26-Oct-2026 09:04:01
BIOCON : SECURES MARKET ENTRY RIGHTS FOR YESINTEK BIOSIMILAR IN 9 ADDITIONAL GLOBAL MARKETS
• License Agreement: Signed agreement with Janssen Sciences Ireland for commercialization of Yesintek, a proposed biosimilar to Stelara (Ustekinumab) • New Markets: Secured commercialization rights in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan • Global Expansion: Builds on existing market entry agreements covering the US, Europe, UK, Canada and Japan • Market Opportunity: Reference drug Stelara recorded worldwide sales of $6.08 billion in 2025 • Therapeutic Applications: Yesintek targets Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis • Growth Potential: Expanded geographical reach strengthens Biocon's global biosimilars portfolio and long-term revenue opportunities • Regulatory Approvals: Commercial launches in the additional markets remain subject to regulatory approvals
GLOBAL CAPITAL MARKETS LTD.